Advanced hydrogels: New expectation for the repair of organic erectile dysfunction.
Erectile dysfunction
Hydrogel
Neural regeneration
Tissue repair
Vascular regeneration
Journal
Materials today. Bio
ISSN: 2590-0064
Titre abrégé: Mater Today Bio
Pays: England
ID NLM: 101757228
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
21
12
2022
revised:
08
02
2023
accepted:
18
02
2023
entrez:
10
3
2023
pubmed:
11
3
2023
medline:
11
3
2023
Statut:
epublish
Résumé
Organic erectile dysfunction (ED) is a type of sexual disorder in men that is usually associated with illness, surgical injury, normal aging and has a high incidence across the globe. And the essence of penile erection is a neurovascular event regulated by a combination of factors. Nerve and vascular injury are the main causes of erectile dysfunction. Currently, the main treatment options for ED include phosphodiesterase type 5 inhibitors (PDE5Is), intracorporeal injections and vacuum erection devices (VEDs), which are ineffective. Therefore, it is essential to find an emerging, non-invasive and effective treatment for ED. The histopathological damage causing ED can be improved or even reversed with hydrogels, in contrast to current therapies. Hydrogels have many advantages, they can be synthesized from various raw materials with different properties, possess a definite composition, and have good biocompatibility and biodegradability. These advantages make hydrogels an effective drug carrier. In this review, we began with an overview of the underlying mechanisms of organic erectile dysfunction, discussed the dilemmas of existing treatments for ED, and described the unique advantages of hydrogel over other approaches. Then emphasizing the progress of research on hydrogels in the treatment of ED.
Identifiants
pubmed: 36896414
doi: 10.1016/j.mtbio.2023.100588
pii: S2590-0064(23)00048-0
pmc: PMC9988670
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
100588Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Pharmaceutics. 2020 Nov 04;12(11):
pubmed: 33158184
Exp Neurol. 2019 Feb;312:10-19
pubmed: 30391523
Nat Med. 2020 Feb;26(2):252-258
pubmed: 32042192
Nat Rev Urol. 2018 May;15(5):287-307
pubmed: 29532805
Adv Sci (Weinh). 2022 Apr;9(10):e2104165
pubmed: 35142093
Curr Pharm Des. 2015;21(12):1627-32
pubmed: 25594403
J Sex Med. 2009 Feb;6(2):415-28
pubmed: 19138364
J Sex Med. 2021 Apr;18(4):711-722
pubmed: 33707045
Adv Mater. 2017 Nov;29(44):
pubmed: 29044686
J Sex Med. 2013 May;10(5):1240-50
pubmed: 22994531
J Sex Med. 2019 Oct;16(10):1490-1505
pubmed: 31447380
J Sex Med. 2015 Jun;12(6):1309-18
pubmed: 25872648
J Control Release. 2021 Jan 10;329:16-35
pubmed: 33259851
Nat Commun. 2020 Jun 1;11(1):2687
pubmed: 32483116
Nat Rev Dis Primers. 2016 Feb 04;2:16003
pubmed: 27188339
Korean J Urol. 2014 May;55(5):295-9
pubmed: 24868332
N Engl J Med. 2000 Jun 15;342(24):1802-13
pubmed: 10853004
Nanomedicine. 2017 Jan;13(1):95-101
pubmed: 27609775
Bioact Mater. 2021 Aug 09;9:147-156
pubmed: 34820562
Theranostics. 2019 Aug 14;9(22):6354-6368
pubmed: 31588222
J Urol. 2003 Mar;169(3):1175-9
pubmed: 12576876
N Engl J Med. 2015 Aug 20;373(8):689-91
pubmed: 26287846
Br J Radiol. 2021 Mar 01;94(1119):20200433
pubmed: 33586999
Nat Neurosci. 2017 Apr 25;20(5):637-647
pubmed: 28440805
Eur Urol. 2010 May;57(5):804-14
pubmed: 20189712
Carbohydr Polym. 2023 Jan 15;300:120226
pubmed: 36372471
Bioeng Transl Med. 2022 May 31;7(3):e10319
pubmed: 36176612
Biomaterials. 2021 Jan;265:120448
pubmed: 33068892
Curr Opin Biotechnol. 2016 Aug;40:155-163
pubmed: 27162093
Macromol Biosci. 2021 Feb;21(2):e2000307
pubmed: 33241641
Sci Bull (Beijing). 2018 Jan 30;63(2):92-100
pubmed: 36658930
Bioact Mater. 2021 Nov 02;12:16-29
pubmed: 35087960
Biomed Pharmacother. 2021 Feb;134:111128
pubmed: 33348311
Eur Urol. 2016 Aug;70(2):301-11
pubmed: 26850969
N Engl J Med. 2008 Mar 20;358(12):1250-61
pubmed: 18354103
Eur Urol. 2021 Sep;80(3):333-357
pubmed: 34183196
Acta Biomater. 2016 Mar 01;32:89-99
pubmed: 26776147
J Urol. 2018 Sep;200(3):633-641
pubmed: 29746858
Nat Rev Urol. 2010 Mar;7(3):162-72
pubmed: 20157304
J Sex Med. 2013 Jan;10(1):130-71
pubmed: 23343170
Ann Intern Med. 2003 Aug 5;139(3):161-8
pubmed: 12899583
Urol Clin North Am. 2005 Nov;32(4):379-95, v
pubmed: 16291031
Eur Urol. 2017 Feb;71(2):223-233
pubmed: 27321373
Adv Mater. 2017 Feb;29(8):
pubmed: 27982464
Eur Urol. 2014 May;65(5):968-78
pubmed: 24011423
Nanomedicine. 2018 Oct;14(7):2087-2094
pubmed: 30037776
Eur Heart J. 2013 Jul;34(27):2034-46
pubmed: 23616415
Curr Opin Urol. 2017 Nov;27(6):511-515
pubmed: 28816715
Nat Mater. 2010 Jul;9(7):594-601
pubmed: 20543836
Nat Rev Urol. 2022 Feb;19(2):84-100
pubmed: 34764451
World J Urol. 2019 Jun;37(6):1007-1014
pubmed: 30895359
Bioact Mater. 2018 May 28;3(4):389-400
pubmed: 30003178
J Sex Med. 2014 Oct;11(10):2589-94
pubmed: 25070914
Asian J Androl. 2020 Jan-Feb;22(1):39-44
pubmed: 31793445
N Engl J Med. 2016 Oct 13;375(15):1425-1437
pubmed: 27626365
Sex Med Rev. 2020 Apr;8(2):333-337
pubmed: 31278064
Nanomedicine. 2021 Oct;37:102444
pubmed: 34314869
J Sex Med. 2010 Jan;7(1 Pt 2):524-40
pubmed: 20092451
Pharmazie. 2006 Nov;61(11):933-7
pubmed: 17152986
Biol Reprod. 2007 Jan;76(1):19-28
pubmed: 16988214
Int J Mol Sci. 2021 Jan 03;22(1):
pubmed: 33401548
Am J Cardiol. 2005 Dec 26;96(12B):19M-23M
pubmed: 16387561
J Sex Med. 2017 Jan;14(1):36-43
pubmed: 28065359
Rev Endocr Metab Disord. 2020 Dec;21(4):657-666
pubmed: 32002782
Andrology. 2021 Jul;9(4):1053-1059
pubmed: 33742540
Int J Impot Res. 2019 May;31(3):177-194
pubmed: 30664671
Tissue Eng Part A. 2014 Sep;20(17-18):2446-54
pubmed: 24673637
Med J Aust. 2019 Jun;210(10):469-476
pubmed: 31099420
Nat Rev Urol. 2019 Dec;16(12):734-744
pubmed: 31649327
Eur Urol. 2011 May;59(5):784-96
pubmed: 21354696
Bioact Mater. 2020 Oct 10;6(4):998-1011
pubmed: 33102942
Mater Sci Eng C Mater Biol Appl. 2020 Nov;116:111214
pubmed: 32806303
J Liposome Res. 2016 Dec;26(4):288-96
pubmed: 26784833
Nat Rev Urol. 2022 Sep;19(9):534-546
pubmed: 35711059
Disabil Rehabil. 2010;32(14):1204-8
pubmed: 20156044
Lancet. 2013 Jan 12;381(9861):153-65
pubmed: 23040455
Small. 2012 May 21;8(10):1596-606
pubmed: 22411637
Drug Des Devel Ther. 2015 Apr 29;9:2431-47
pubmed: 25995616
J Clin Invest. 2021 Feb 15;131(4):
pubmed: 33586676
J Sex Med. 2011 Jan;8(1):78-89
pubmed: 20807324
Biomaterials. 2011 Feb;32(4):1091-101
pubmed: 20971506
Nat Commun. 2015 Jan 23;6:5988
pubmed: 25612916
Nat Rev Urol. 2016 May;13(5):266-74
pubmed: 26878803
Int J Impot Res. 2010 Jul-Aug;22(4):211-9
pubmed: 20410903
Nanoscale. 2019 Oct 3;11(38):17782-17790
pubmed: 31552990
J Sex Med. 2010 Jan;7(1 Pt 1):224-33
pubmed: 19765204
Circulation. 2019 Sep 10;140(11):e596-e646
pubmed: 30879355
ACS Nano. 2019 Dec 24;13(12):14283-14293
pubmed: 31769966
J Sex Med. 2016 Apr;13(4):465-88
pubmed: 27045254
Urology. 2014 Nov;84(5):1248.e1-7
pubmed: 25443945
Nat Rev Cardiol. 2022 Jan;19(1):59-74
pubmed: 34331033
J Biomed Nanotechnol. 2019 Oct 1;15(10):2108-2120
pubmed: 31462375
Postgrad Med J. 2017 Nov;93(1105):679-685
pubmed: 28751439
Tissue Eng Part A. 2013 Jan;19(1-2):14-23
pubmed: 22834730
Tissue Eng Part A. 2018 Dec;24(23-24):1705-1714
pubmed: 30152718
J Androl. 2003 Sep-Oct;24(5):688-98
pubmed: 12954659
J Control Release. 2020 Apr 10;320:337-346
pubmed: 31931048
Lancet Neurol. 2022 Jun;21(6):551-562
pubmed: 35405093
Int J Impot Res. 2008 Nov-Dec;20(6):566-73
pubmed: 18997809
Nanomedicine. 2019 Aug;20:102033
pubmed: 31173931
Neurosci Lett. 2013 Apr 29;541:248-52
pubmed: 23416899
J Sex Med. 2014 Dec;11(12):2903-14
pubmed: 25302850
Colloids Surf B Biointerfaces. 2023 Feb;222:113018
pubmed: 36435027
BJU Int. 2021 Mar;127(3):326-331
pubmed: 32869902
J Sex Med. 2012 Sep;9(9):2361-9
pubmed: 22616766
Int Urol Nephrol. 2019 Feb;51(2):223-229
pubmed: 30547361
J Am Coll Cardiol. 2016 Feb 9;67(5):545-57
pubmed: 26846952